b'Analyses have been done with reference to these factors, notably for psilocybin by a group of researchers lead by Dr. Jack Henningfield 4 , to determine how accurately scheduling reflects their abuse potential and therapeutic use in isolation from their social and political history. Whilepsilocybinis currentlyaScheduleI drugintheU.S., careful analysis places it more appropriately as Schedule IV. In addition, there is a growing movement advocating for drug scheduling reform for the sake of enabling more research into drugs with therapeutic potential 5 . Another shift on the horizon is the development of second-generation psychedelicsthatmayprovidemedicalbenefitswithoutthe hallucinogenic properties, which would lower the risk of abuse. If this potential is actualized, there could be a whole new class of psychedelic drugs that dont need to be placed on such restrictive schedules.As the social landscape continues to shift, more research is done, and new drugs with greater therapeutic potential and less risk of abuse enter the market, a loosening of restrictions in the future becomes increasingly likely.1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603818/2. https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/exemptions/application-form-exemption-use-controlled-substance-scientific-purposes.html 3. https://www.dea.gov/sites/default/files/drug_of_abuse.pdf4. https://pubmed.ncbi.nlm.nih.gov/29753748/5. https://bmcinthealthhumrights.biomedcentral.com/articles/10.1186/s12914-020-00231-1'